Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone626-304-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.14 million
Profitability
Miscellaneous
Employees116
Next Earnings Date12/10/2019 (Estimated)
OptionableOptionable
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced its earnings results on Monday, August, 5th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.34 by $0.13. The biotechnology company had revenue of $42.70 million for the quarter, compared to analyst estimates of $59.05 million. Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
5 analysts have issued 1-year target prices for Arrowhead Pharmaceuticals' stock. Their forecasts range from $24.00 to $50.00. On average, they anticipate Arrowhead Pharmaceuticals' stock price to reach $36.1250 in the next twelve months. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for Arrowhead Pharmaceuticals.
What is the consensus analysts' recommendation for Arrowhead Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arrowhead Pharmaceuticals.
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
News stories about ARWR stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arrowhead Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Arrowhead Pharmaceuticals.
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Array Biopharma (ARRY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE), Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY) and Beigene (BGNE).
What other stocks do shareholders of Arrowhead Pharmaceuticals own?
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 50)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 53)
- Dr. Bruce D. Given, Chief Operating Officer (Age 65)
- Mr. Patrick O'Brien, Gen. Counsel (Age 55)
- Dr. Mark M. Davis, Founder and Founder & Director of Insert Therapeutics Inc & Calando
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.65%), BlackRock Inc. (15.65%), Vanguard Group Inc. (9.11%), Invesco Ltd. (5.08%), First Manhattan Co. (3.25%) and Vivo Capital LLC (2.92%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Uniplan Investment Counsel Inc., DekaBank Deutsche Girozentrale, Candriam Luxembourg S.C.A., Fiera Capital Corp, ClariVest Asset Management LLC, Allianz Asset Management GmbH and Bailard Inc.. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given, Kenneth Allen Myszkowski, Mauro Ferrari, Michael S Perry, Patrick O'brien, Peter Brian Leone, William D Waddill and Zhen Li. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., BlackRock Inc., Invesco Ltd., Vanguard Group Inc., Bank of New York Mellon Corp, Renaissance Technologies LLC, Vivo Capital LLC and Nuveen Asset Management LLC. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $29.95.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $2.84 billion and generates $16.14 million in revenue each year. The biotechnology company earns $-54,450,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. Arrowhead Pharmaceuticals employs 116 workers across the globe.View Additional Information About Arrowhead Pharmaceuticals.
What is Arrowhead Pharmaceuticals' official website?
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (NASDAQ ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
